<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with indolent non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (I-NHL) often receive multiple courses of cytotoxic chemotherapy over several years </plain></SENT>
<SENT sid="1" pm="."><plain>Radioimmunotherapy (RIT) has become an important part of treatment for relapsed patients and tositumomab/lodine I-131 tositumomab is a promising regimen currently being incorporated into first-line therapy </plain></SENT>
<SENT sid="2" pm="."><plain>While treatment-related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (tMDS) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (tAML) are well-known, poor-prognosis complications of conventional chemotherapy and radiation therapy, they have not been previously observed as a consequence of initial treatment with RIT-based regimens </plain></SENT>
<SENT sid="3" pm="."><plain>We describe four patients with tMDS/tAML who received a sequential chemotherapy and tositumomab/lodine I-131 tositumomab program as their initial and only <z:hpo ids='HP_0002665'>lymphoma</z:hpo> treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Our findings suggest that the potential risk of these important complications must be considered in the development of this novel therapeutic strategy in the first-line setting </plain></SENT>
</text></document>